Product Liability Lawsuit Funding in Washington

Washington gives an injured plaintiff three years from the time the harm was discovered, or reasonably should have been discovered, to bring a claim under the Washington Product Liability Act (RCW 7.72.060(3)). Washington does not impose a hard statute of repose, but RCW 7.72.060(1)–(2) creates a rebuttable presumption that a product is not defective if the harm occurred after the product's 'useful safe life' — presumptively 12 years after delivery to its first purchaser or lessee — expired, unless the claimant rebuts that presumption by a preponderance of the evidence. The presumption does not apply where the manufacturer expressly warranted a longer safe life, intentionally misrepresented or concealed facts about the product, or where the claimant's exposure to the defective product occurred within the useful safe life even though the harm did not manifest until later.

Washington applies pure comparative fault (RCW 4.22.005), meaning a plaintiff's own fault reduces recovery proportionally but never bars it outright, regardless of the plaintiff's percentage of fault. The Washington Product Liability Act incorporates Washington's general fault-apportionment framework into a strict-liability product claim; the exact statutory cross-reference establishing that incorporation should be confirmed against the current RCW text and case law for the specific claim, since it is not contained in the useful-safe-life repose provision itself.

Washington has no cap on non-economic or compensatory damages in a product liability action; the Washington Supreme Court struck down the state's general damages cap as unconstitutional in Sofie v. Fibreboard Corp., 112 Wash. 2d 636 (1989).

Pre-judgment interest is generally unavailable on unliquidated personal-injury damages in Washington.

Product liability suits are typically filed in the Washington county where the claim arose or where a defendant resides or has a place of business (RCW 4.12.020, 4.12.025). Because manufacturer defendants are frequently incorporated and headquartered outside Washington, an out-of-state manufacturer can support removal to federal court on diversity grounds (28 U.S.C. §1332) as an alternative to the state venue rule.

Washington has no dedicated consumer litigation funding statute. No statutory cap.

How does Washington's useful-safe-life presumption affect funding for an older product?

If the product's useful safe life has expired — presumptively 12 years after it was first delivered — Washington law presumes it was not defective, so the plaintiff has to rebut that presumption or show the manufacturer warranted a longer life, misrepresented facts about the product, or that exposure occurred within the safe-life window even though the harm appeared later.

A funding decision on an older-product Washington claim typically turns on which of these rebuttal paths is realistically available, since the presumption otherwise makes the claim significantly harder to sustain past the 12-year mark.

Does Washington's pure comparative-fault rule make underwriting more forgiving than in a bar-threshold state?

Yes, in relative terms. Because a plaintiff's fault only reduces damages and never eliminates them outright in Washington, a case with some misuse evidence still typically produces a recoverable, fundable claim rather than an all-or-nothing outcome.

This is a meaningfully different risk profile from a modified comparative-fault state with a 50% or 51% bar, and it is a factor that generally supports funding availability for Washington claims that would be riskier to fund elsewhere.

Why does the absence of a damages cap matter for a serious Washington product injury?

Since Sofie v. Fibreboard struck down Washington's general damages cap, there is no statutory ceiling on non-economic damages, which is particularly significant in a catastrophic-injury product case where pain-and-suffering damages can be substantial.

This uncapped exposure is a meaningful factor in valuing a serious Washington product claim, alongside the underlying defect theory and the useful-safe-life analysis described above.